How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/haemophilus-parainfluenzae-chronic-bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Haemophilus Parainfluenzae Chronic Bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Haemophilus Parainfluenzae Chronic Bronchitis (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Haemophilus Parainfluenzae Chronic Bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	Cephalosporin Antibacterial		2001-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Avelox	Avelox	Novartis Pharmaceuticals		DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Haemophilus Parainfluenzae Chronic Bronchitis
GSK · 2 drugs in Haemophilus Parainfluenzae Chronic Bronchitis
Allergan · 1 drug in Haemophilus Parainfluenzae Chronic Bronchitis
Bayer AG · 1 drug in Haemophilus Parainfluenzae Chronic Bronchitis
Novartis Pharmaceuticals · 1 drug in Haemophilus Parainfluenzae Chronic Bronchitis
Vansen Pharma · 1 drug in Haemophilus Parainfluenzae Chronic Bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Haemophilus Parainfluenzae Chronic Bronchitis:

Cite this brief

Drug Landscape (2026). Haemophilus Parainfluenzae Chronic Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/haemophilus-parainfluenzae-chronic-bronchitis. Accessed 2026-06-11.

Haemophilus Parainfluenzae Chronic Bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing